Preoperative autologous blood donations in pediatric cardiac surgery.

Monetaka Masuda,Yosito Kawachi,Shouiti Inaba,Kouji Matsuzaki,Fumio Fukumura,Shigeki Morita,Ryuji Tominaga,Hisataka Yasui

DOI: https://doi.org/10.1016/0003-4975(95)00715-6

1995-12-01

Abstract:

What problem does this paper attempt to address?

Next Generation Sequencing in Children with Unexplained Epilepsy: A Retrospective Cohort Study.

Wenjie Chen,Jiong Qin,Yiping Shen,Jingjing Liang,Yanan Cui,Ying Zhang

DOI: https://doi.org/10.1016/j.braindev.2021.05.014

IF: 2.272

2021-01-01

Brain and Development

Abstract:Objective: To evaluate the clinical utility of next-generation sequencing (NGS) in unexplained pediatric epilepsy, and to identify the potential predictors associated with Mendelian genetic causes. Methods: Two hundred and ten children with unexplained epilepsy, who underwent NGS test were included. We analyzed the demographic, clinical and genetic characteristics, and executed a Logistic regression analysis for identifying predictors for Mendelian genetic causes. Patients were classified as either with isolated epilepsy or syndromic epilepsy with concurrent neurodevelopmental phenotypes. Results: The overall diagnostic yield was 29.0% (61/210). A total of 68 variants spanning 39 genes were identified in 58 patients (27.6%, 58/210) from exome sequencing based testing. Of the 68 variants, 33 were novel ones. Besides, STAR and CNTN2 were identified to be a candidate gene for epilepsy. Patients with syndromic epilepsy had a much higher diagnostic yield than that of isolated epilepsy (53/135, 39.3% vs. 8/75, 10.7%, p = 0.000). The odds ratio of detecting genetic cause was 3.939 (95% CI 1.369-11.332) for syndromic epilepsy without epileptic encephalopathy (EE), 5.814 (95% CI 2.208-15.306) for EE, 2.958 (95% CI 1.093-8.000) for patients with seizure onset <12 months, and 2.932 (95%CI 1.414-6.080) for female. Of the 210 patients, 78.4% of patients (145/185) had at least a 50% reduction in seizure frequency and 58.9% (109/185) reached seizure freedom. There was no difference between seizure prognosis and diagnostic outcomes. Significance: NGS is effective for Mendelian genetic etiological diagnosis for unexplained pediatric epilepsy. Female patients with syndromic epilepsy with onset within the first year of life are most likely to yield a positive test result. (C) 2021 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.
Clinical Utility of Exome Sequencing and Reinterpreting Genetic Test Results in Children and Adults With Epilepsy

Yong-li Jiang,Changgeng Song,Yuanyuan Wang,Jingjing Zhao,Fang Yang,Qiong Gao,Xiuxiu Leng,Yulin Man,Wen Jiang

DOI: https://doi.org/10.3389/fgene.2020.591434

IF: 3.7

2020-12-18

Frontiers in Genetics

Abstract:The clinical utility of genetic testing for epilepsy has been enhanced with the advancement of next-generation sequencing (NGS) technology along with the rapid updating of publicly available databases. The aim of this study was to evaluate the diagnostic yield of NGS and assess the value of reinterpreting genetic test results in children and adults with epilepsy. We performed genetic testing on 200 patients, including 82 children and 118 adults. The results were classified into three categories: positive, inconclusive, or negative. The reinterpretation of inconclusive results was conducted in April 2020. Overall, we identified disease-causing variants in 12% of the patients in the original analysis, and 14.5% at reinterpretation. The diagnostic yield for adults with epilepsy was similar to that for children (11 vs. 19.5%, p = 0.145). After reinterpretation, 9 of the 86 patients who initially had inconclusive results obtained a clinically significant change in diagnosis. Among these nine revised cases, five obtained positive diagnoses, representing a diagnosis rate of 5.8% (5/86). Manual searches for additional evidence of pathogenicity for candidate variants and updated patient clinical information were the main reasons for diagnostic reclassification. This study emphasizes the diagnostic potential of combining NGS and reinterpretation of inconclusive genetic test reports in children and adults with epilepsy.

genetics & heredity
Cowpea embryo rescue. 1. Influence of culture media composition on plant recovery from isolated immature embryos

A. Pellegrineschi,C. Fatokun,G. Thottappilly,A. Adepoju

DOI: https://doi.org/10.1007/s002990050366

IF: 6.2

1997-12-01

Plant Cell Reports

Abstract:
Next-generation sequencing testing in children with epilepsy reveals novel clinical, diagnostic and therapeutic implications

Magdalena Krygier,Marta Pietruszka,Marta Zawadzka,Agnieszka Sawicka,Anna Lemska,Monika Limanówka,Jan Żurek,Weronika Talaśka-Liczbik,Maria Mazurkiewicz-Bełdzińska

DOI: https://doi.org/10.3389/fgene.2023.1300952

IF: 3.7

2024-01-06

Frontiers in Genetics

Abstract:Introduction: Epilepsy is one of the commonest diseases in children, characterized by extensive phenotypic and genetic heterogeneity. This study was conducted to determine the diagnostic utility and to identify novel clinical and therapeutic implications of genetic testing in pediatric patients with epilepsy. Methods: Large multigene panel and/or exome sequencing was performed in 127 unrelated Polish and Ukrainian patients with suspected monogenic epilepsy. Diagnostic yields were presented for five phenotypic subgroups, distinguished by seizure type, electroencephalographic abnormalities, anti-seizure treatment response, and neurodevelopmental deficits. Results: A definite molecular diagnosis was established in 46 out of 127 cases (36%). Alterations in six genes were detected in more than one patient: SCN1A , MECP2 , KCNT1 , KCNA2 , PCDH19 , SLC6A1 , STXBP1 , and TPP1 , accounting for 48% of positive cases. 4/46 cases (8.7%) were mosaic for the variant. Although the highest rates of positive diagnoses were identified in children with developmental delay and generalized seizures (17/41, 41%) and in developmental end epileptic encephalopathies (16/40, 40%), a monogenic etiology was also frequently detected in patients with solely focal seizures (10/28, 36%). Molecular diagnosis directly influenced anti-seizure management in 15/46 cases. Conclusion: This study demonstrates the high diagnostic and therapeutic utility of large panel testing in childhood epilepsies irrespective of seizure types. Copy number variations and somatic mosaic variants are important disease-causing factors, pointing the need for comprehensive genetic testing in all unexplained cases. Pleiotropy is a common phenomenon contributing to the growing phenotypic complexity of single-gene epilepsies.

genetics & heredity
High Diagnostic Yield and Clinical Utility of Next-Generation Sequencing in Children with Epilepsy and Neurodevelopmental Delays: A Retrospective Study

Daniel Charouf,Derryl Miller,Laith Haddad,Fletcher A White,Rose-Mary Boustany,Makram Obeid

DOI: https://doi.org/10.3390/ijms25179645

2024-09-06

Abstract:Advances in genetics led to the identification of hundreds of epilepsy-related genes, some of which are treatable with etiology-specific interventions. However, the diagnostic yield of next-generation sequencing (NGS) in unexplained epilepsy is highly variable (10-50%). We sought to determine the diagnostic yield and clinical utility of NGS in children with unexplained epilepsy that is accompanied by neurodevelopmental delays and/or is medically intractable. A 5-year retrospective review was conducted at the American University of Beirut Medical Center to identify children who underwent whole exome sequencing (WES) or whole genome sequencing (WGS). Data on patient demographics, neurodevelopment, seizures, and treatments were collected. Forty-nine children underwent NGS with an overall diagnostic rate of 68.9% (27/38 for WES, and 4/7 for WGS). Most children (42) had neurodevelopmental delays with (18) or without (24) refractory epilepsy, and only three had refractory epilepsy without delays. The diagnostic yield was 77.8% in consanguineous families (18), and 61.5% in non-consanguineous families (26); consanguinity information was not available for one family. Genetic test results led to anti-seizure medication optimization or dietary therapies in six children, with subsequent improvements in seizure control and neurodevelopmental trajectories. Not only is the diagnostic rate of NGS high in children with unexplained epilepsy and neurodevelopmental delays, but also genetic testing in this population may often lead to potentially life-altering interventions.
Utility of Genome Sequencing After Nondiagnostic Exome Sequencing in Unexplained Pediatric Epilepsy

Alissa M D'Gama,Wanqing Shao,Lacey Smith,Hyun Yong Koh,Maya Davis,Julia Koh,Brandon T Oby,Cesar I Urzua,Beth R Sheidley,Shira Rockowitz,Annapurna Poduri

DOI: https://doi.org/10.1101/2024.08.08.24307445

2024-08-09

Abstract:Importance: Epilepsy is the most common neurological disorder of childhood. Identifying genetic diagnoses underlying epilepsy is critical to developing effective therapies and improving outcomes. Most children with non-acquired (unexplained) epilepsy remain genetically unsolved, and the utility of genome sequencing after nondiagnostic exome sequencing is unknown. Objective: To determine the diagnostic (primary) and clinical (secondary) utility of genome sequencing after nondiagnostic exome sequencing in individuals with unexplained pediatric epilepsy. Design: This cohort study performed genome sequencing and comprehensive analyses for 125 participants and available biological parents enrolled from August 2018 to May 2023, with data analysis through April 2024 and clinical return of diagnostic and likely diagnostic genetic findings. Clinical utility was evaluated. Setting: Pediatric referral center Participants: Participants with unexplained pediatric epilepsy and previous nondiagnostic exome sequencing; biological parents when available Exposure(s): Short-read genome sequencing and analysis Main Outcome(s) and Measure(s): Primary outcome measures were the diagnostic yield of genome sequencing, defined as the percentage of participants receiving a diagnostic or likely diagnostic genetic finding, and the unique diagnostic yield of genome sequencing, defined as the percentage of participants receiving a diagnostic or likely diagnostic genetic finding that required genome sequencing. The secondary outcome measure was clinical utility of genome sequencing, defined as impact on evaluation, treatment, or prognosis for the participant or their family. Results: 125 participants (58 [46%] female) were enrolled with median age at seizure onset 3 [IQR 1.25, 8] years, including 44 (35%) with developmental and epileptic encephalopathies. The diagnostic yield of genome sequencing was 7.2% (9/125), with diagnostic genetic findings in five cases and likely diagnostic genetic findings in four cases. Among the solved cases, 7/9 (78%) required genome sequencing for variant detection (small copy number variant, three noncoding variants, and three difficult to sequence small coding variants), for a unique diagnostic yield of genome sequencing of 5.6% (7/125). Clinical utility was documented for 4/9 solved cases (44%). Conclusions and Relevance: These findings suggest that genome sequencing can have diagnostic and clinical utility after nondiagnostic exome sequencing and should be considered for patients with unexplained pediatric epilepsy.

Neurology
Identification of genetic causes in children with unexplained epilepsy based on trio‐whole exome sequencing

Li Chengyan,Xue Chupeng,Wang You,Chen Yinhui,Huang Binglong,Ao Dang,Liu Ling,Tian Chuan

DOI: https://doi.org/10.1111/cge.14519

2024-03-13

Clinical Genetics

Abstract:Overall flow chart of genetic diagnosis for 135 individuals with unexplained epilepsy. Genotype and clinical phenotype analyses of 128 children were performed based on whole exome sequencing (WES), providing a reference for the provision of genetic counseling and the precise diagnosis and treatment of epilepsy. A total of 128 children with unexplained epilepsy were included in this study, and all their clinical data were analyzed. The children's treatments, epilepsy control, and neurodevelopmental levels were regularly followed up every 3 months. The genetic diagnostic yield of the 128 children with epilepsy is 50.8%, with an SNV diagnostic yield of 39.8% and a CNV diagnostic yield of 12.5%. Among the 128 children with epilepsy, 57.0% had onset of epilepsy in infancy, 25.8% have more than two clinical seizure forms, 62.5% require two or more anti‐epileptic drug treatments, and 72.7% of the children have varying degrees of psychomotor development retardation. There are significant differences between ages of onset, neurodevelopmental levels and the presence of drug resistance in the genetic diagnostic yield (all p

genetics & heredity
C.1 Utility of genetic testing in the pre-surgical evaluation of children with drug-resistant epilepsy

S Alsubhi

DOI: https://doi.org/10.1017/cjn.2024.86

2024-05-24

Abstract:Background: All patients with drug-resistant focal epilepsy, should undergo an evaluation to determine if non-medical options, including surgical intervention, are appropriate. This evaluation involves a thorough work-up, typically including some or all of neuropsychological evaluation, prolonged video EEG monitoring, and advanced neuroimaging. The utility of genetic testing as part of this evaluation has not been thoroughly investigated. Methods: In this retrospective study, we reviewed the charts of pediatric patients referred for epilepsy surgery evaluation over a 5-year period. We extracted and analyzed results of genetic testing as well as clinical, EEG, and neuroimaging data. Results: 125 patients were referred for epilepsy surgical evaluation, 86 of whom had some form of genetic testing. Of these, 18 had a pathogenic or likely pathogenic variant identified. Genes affected included NPRL3, TSC2, KCNH1, CHRNA4, SPTAN1, DEPDC5, SCN2A, ARX, SCN1A, DLG4, and ST5. One patient had ring chromosome 20, one a 7.17p12 duplication, and one a 15q13 deletion. A specific medical therapy choice was allowed due to genetic diagnosis in three patients who did not undergo surgery. Conclusions: Obtaining a molecular diagnosis may dramatically alter management in children with drug-resistant focal epilepsy. Genetic testing should be incorporated as part of standard investigations in the pre-surgical work-up of such patients.
Genetic testing in a cohort of patients with potential epilepsy with myoclonic-atonic seizures

Katie Angione,Krista Eschbach,Garnett Smith,Charuta Joshi,Scott Demarest

DOI: https://doi.org/10.1016/j.eplepsyres.2019.01.008

Abstract:Epilepsy with myoclonic-atonic seizures (EMAS) accounts for 1-2% of all childhood-onset epilepsies. EMAS has been shown to have an underlying genetic component, however the genetics of this disorder is not yet well understood. The purpose of this study was to review genetic testing results for a cohort of EMAS patients. A retrospective chart review was conducted for 77 patients evaluated at Children's Hospital Colorado with a potential diagnosis of EMAS. Genetic testing and biochemical testing was reviewed. Family history data was also collected. Seventy-seven percent of the cohort had at least one genetic test performed, and a molecular diagnosis was reached for six patients. Thirty-seven patients had a microarray, six of which identified a copy number variant. Only one was felt to contribute to the phenotype (2p16.3 deletion including NRXN1). Fifty-one patients had an epilepsy panel, two of which were positive (likely pathogenic variant in SCN1A, pathogenic variant in GABRG2). Of the six patients who had whole exome sequencing, two were negative, three were positive or likely positive, and one had multiple variants not felt to explain the phenotype. While EMAS is widely accepted to have a strong genetic component, the diagnostic yield of genetic testing remains low. This may be because several genes now thought to be associated with EMAS are not included on the more commonly ordered epilepsy panels, or have only recently been added to them.
Genetic Testing in the Presurgical Evaluation of Drug-Resistant Epilepsy: Bells and Whistles or Nuts and Bolts?

Ioannis Karakis

DOI: https://doi.org/10.1177/15357597241250161

2024-05-01

Epilepsy Currents

Abstract:Epilepsy Currents, Ahead of Print. Genetic Testing in Children Enrolled in Epilepsy Surgery Program. A Real-Life Study Straka B, Splitkova B, Vlckova M, Tesner P, Rezacova H, Krskova L, Koblizek M, Kyncl M, Maulisova A, Bukacova K, Uhrova-Meszarosova A, Musilova A, Kudr M, Ebel M, Belohlavkova A, Jahodova A, Liby P, Tichy M, Jezdik P, Zamecnik J, Aronica E, Krsek P. Eur J Paediatr Neurol. 2023;47:80-87. doi:10.1016/j.ejpn.2023.09.009. PMID: 37812946 Objective:Although genetic causes of drug-resistant focal epilepsy and selected focal malformations of cortical development (MCD) have been described, a limited number of studies comprehensively analysed genetic diagnoses in patients undergoing pre-surgical evaluation, their outcomes and the effect of genetic diagnosis on surgical strategy.Methods:We analysed a prospective cohort of children enrolled in epilepsy surgery program over January 2018-July 2022. The majority of patients underwent germline and/or somatic genetic testing. We searched for predictors of surgical outcome and positive result of germline genetic testing.Results:Ninety-five patients were enrolled in epilepsy surgery program and 64 underwent resective epilepsy surgery. We ascertained germline genetic diagnosis in 13/74 patients having underwent germline gene testing (pathogenic or likely pathogenic variants in CHRNA4, NPRL3, DEPDC5, FGF12, GRIA2, SZT2, STXBP1) and identified three copy number variants. Thirty-five patients underwent somatic gene testing; we detected 10 pathogenic or likely pathogenic variants in genes SLC35A2, PTEN, MTOR, DEPDC5, NPRL3. Germline genetic diagnosis was significantly associated with the diagnosis of focal epilepsy with unknown seizure onset.Significance:Germline and somatic gene testing can ascertain a definite genetic diagnosis in a significant subgroup of patients in epilepsy surgery programs. Diagnosis of focal genetic epilepsy may tip the scales against the decision to proceed with invasive EEG study or surgical resection; however, selected patients with genetic focal epilepsies associated with MCD may benefit from resective epilepsy surgery and therefore, a genetic diagnosis does not disqualify patients from presurgical evaluation and epilepsy surgery. Utility of Genetic Testing in the Pre-Surgical Evaluation of Children With Drug-Resistant Epilepsy Alsubhi S, Berrahmoune S, Dudley RWR, Dufresne D, Simard Tremblay E, Srour M, Myers KA. J Neurol. 2024. doi:10.1007/s00415-023-12174-3. PMID: 38261030 We evaluated the utility of genetic testing in the pre-surgical evaluation of pediatric patients with drug-resistant focal epilepsy. This single-center retrospective study reviewed the charts of all pediatric patients referred for epilepsy surgery evaluation over a 5-year period. We extracted and analyzed results of genetic testing as well as clinical, EEG, and neuroimaging data. Of 125 patients referred for epilepsy surgical evaluation, 86 (69%) had some form of genetic testing. Of these, 18 (21%) had a pathogenic or likely pathogenic variant identified. Genes affected included NPRL3 (3 patients, all related), TSC2 (3 patients), KCNH1, CHRNA4, SPTAN1, DEPDC5, SCN2A, ARX, SCN1A, DLG4, and ST5. One patient had ring chromosome 20, one a 7.17p12 duplication, and one a 15q13 deletion. In six patients, suspected epileptogenic lesions were identified on brain MRI that were thought to be unrelated to the genetic finding. A specific medical therapy choice was allowed due to genetic diagnosis in three patients who did not undergo surgery. Obtaining a molecular diagnosis may dramatically alter management in pediatric patients with drug-resistant focal epilepsy. Genetic testing should be incorporated as part of standard investigations in the pre-surgical work-up of pediatric patients with drug-resistant focal epilepsy.

clinical neurology
Scientific method in the evolution of new drugs; comparative biochemistry and the selection of possible pharmacologically active compounds.

W. Rogers

Abstract:
Diagnostic yield of genetic testing in epileptic encephalopathy in childhood

Saadet Mercimek-Mahmutoglu,Jaina Patel,Dawn Cordeiro,Stacy Hewson,David Callen,Elizabeth J Donner,Cecil D Hahn,Peter Kannu,Jeff Kobayashi,Berge A Minassian,Mahendranath Moharir,Komudi Siriwardena,Shelly K Weiss,Rosanna Weksberg,O Carter Snead 3rd

DOI: https://doi.org/10.1111/epi.12954

IF: 6.74

Epilepsia

Abstract:Objective: Epilepsy is a common neurologic disorder of childhood. To determine the genetic diagnostic yield in epileptic encephalopathy, we performed a retrospective cohort study in a single epilepsy genetics clinic. Methods: We included all patients with intractable epilepsy, global developmental delay, and cognitive dysfunction seen between January 2012 and June 2014 in the Epilepsy Genetics Clinic. Electronic patient charts were reviewed for clinical features, neuroimaging, biochemical investigations, and molecular genetic investigations including targeted next-generation sequencing of epileptic encephalopathy genes. Results: Genetic causes were identified in 28% of the 110 patients: 7% had inherited metabolic disorders including pyridoxine dependent epilepsy caused by ALDH7A1 mutation, Menkes disease, pyridox(am)ine-5-phosphate oxidase deficiency, cobalamin G deficiency, methylenetetrahydrofolate reductase deficiency, glucose transporter 1 deficiency, glycine encephalopathy, and pyruvate dehydrogenase complex deficiency; 21% had other genetic causes including genetic syndromes, pathogenic copy number variants on array comparative genomic hybridization, and epileptic encephalopathy related to mutations in the SCN1A, SCN2A, SCN8A, KCNQ2, STXBP1, PCDH19, and SLC9A6 genes. Forty-five percent of patients obtained a genetic diagnosis by targeted next-generation sequencing epileptic encephalopathy panels. It is notable that 4.5% of patients had a treatable inherited metabolic disease. Significance: To the best of our knowledge, this is the first study to combine inherited metabolic disorders and other genetic causes of epileptic encephalopathy. Targeted next-generation sequencing panels increased the genetic diagnostic yield from <10% to >25% in patients with epileptic encephalopathy.
Exome sequencing identifies molecular diagnosis in children with drug-resistant epilepsy

Mandy Ho-Yin Tsang,Gordon Ka-Chun Leung,Alvin Chi-Chung Ho,Kit-San Yeung,Christopher Chun-Yu Mak,Steven Lim-Cho Pei,Mullin Ho-Chung Yu,Anita Sik-Yau Kan,Kelvin Yuen-Kwong Chan,Karen Ling Kwong,So-Lun Lee,Ada Wing-Yan Yung,Cheuk-Wing Fung,Brian Hon-Yin Chung

DOI: https://doi.org/10.1002/epi4.12282

2018-12-06

Epilepsia Open

Abstract:Objective: Early onset drug-resistant epilepsy is a neurologic disorder in which 2 antiepileptic drugs fail to maintain the seizure-free status of the patient. Heterogeneous clinical presentations make the diagnosis challenging. We aim to identify the underlying genetic causes of a pediatric cohort with drug-resistant epilepsy and evaluate whether the findings can provide information on patient management. Methods: We include patients with drug-resistant epilepsy onset before 18 years of age. Singleton clinical chromosomal microarray (CMA) followed by whole exome sequencing (WES) was performed using genomic DNA. In the first-tier analysis of the exome data, we aimed to identify disease-causing mutations in 546 genes known to cause, or to be associated with, epilepsy. For negative cases, we proceeded to exome-wide analysis. Rare coding variants were interrogated for pathogenicity based on the American College of Medical Genetics and Genomics (ACMG) guidelines. Results: We recruited 50 patients. We identified 6 pathogenic or likely pathogenic mutations, giving a diagnostic yield of 12%. Mutations were found in 6 different genes: SCN8A, SCN1A, MECP2, CDKL5, DEPDC5, and CHD2. The CDKL5 variant was found to be mosaic. One variant of unknown significance (VUS) in KCNT1 was found in a patient with compatible clinical features. Of note, a reported pathogenic SCN5A mutation known to contribute to Brugada syndrome, was also found in the patient with an SCN1A mutation. Significance: Our study suggests that singleton WES is an effective diagnostic tool for drug-resistant epilepsy. Genetic diagnosis can help to consolidate the clinical diagnosis, to facilitate phenotypic expansion, and to influence treatment and management options for seizure control in our patients. In our study, a significant portion of the genetic findings are known to be associated with an increased risk of sudden unexpected death in epilepsy (SUDEP). These findings could assist with more appropriate management in patients with epilepsy.
Utility of genetic testing in the pre-surgical evaluation of children with drug-resistant epilepsy

Sarah Alsubhi,Saoussen Berrahmoune,Roy W. R. Dudley,David Dufresne,Elisabeth Simard Tremblay,Myriam Srour,Kenneth A. Myers

DOI: https://doi.org/10.1007/s00415-023-12174-3

2024-01-25

Journal of Neurology

Abstract:We evaluated the utility of genetic testing in the pre-surgical evaluation of pediatric patients with drug-resistant focal epilepsy. This single-center retrospective study reviewed the charts of all pediatric patients referred for epilepsy surgery evaluation over a 5-year period. We extracted and analyzed results of genetic testing as well as clinical, EEG, and neuroimaging data. Of 125 patients referred for epilepsy surgical evaluation, 86 (69%) had some form of genetic testing. Of these, 18 (21%) had a pathogenic or likely pathogenic variant identified. Genes affected included NPRL3 (3 patients, all related), TSC2 (3 patients), KCNH1 , CHRNA4 , SPTAN1 , DEPDC5 , SCN2A , ARX , SCN1A , DLG4 , and ST5 . One patient had ring chromosome 20, one a 7.17p12 duplication, and one a 15q13 deletion. In six patients, suspected epileptogenic lesions were identified on brain MRI that were thought to be unrelated to the genetic finding. A specific medical therapy choice was allowed due to genetic diagnosis in three patients who did not undergo surgery. Obtaining a molecular diagnosis may dramatically alter management in pediatric patients with drug-resistant focal epilepsy. Genetic testing should be incorporated as part of standard investigations in the pre-surgical work-up of pediatric patients with drug-resistant focal epilepsy.

clinical neurology
Yield and Utility of Routine Epilepsy Panel Genetic Testing Among Young Patients With Seizures

Emily Grew,Mayuri Reddy,Hayley Reichner,Jinsoo Kim,Misbah Salam,Anjum Hashim

DOI: https://doi.org/10.1177/08830738241240516

2024-03-28

Journal of Child Neurology

Abstract:Journal of Child Neurology, Ahead of Print. Objective: We examined the yield of routine epilepsy panel genetic testing in pediatric patients. Methods: We retrospectively reviewed epilepsy genetic panel results routinely performed in the hospital or clinic on patients <8 years old from July 2021 to July 2023. We evaluated demographics, family history, seizure type, severity, and frequency, development, tone and movement abnormalities, dysmorphism, and electroencephalography (EEG) or magnetic resonance imaging (MRI) results as predictors of results. Results: 65 patients were included with mean age 4.5 years. Sixty percent of patients were male; 11 patients had pathogenic variants (16.9%), 7 were carriers for autosomal recessive conditions (10.8%), 36 had variants of uncertain significance (55.4%), and 11 tested negative (16.9%). Pathogenic variants and variants of uncertain significance were unassociated with demographics, clinical features, imaging, or family history. Conclusion: Variants identified have potential implications for treatment (SCN1), comorbidity screening (TSC1), reproduction (ATAD1, PSAT1, and CLN8), and prognostication (FOXG1). Patients not routinely screened for a genetic cause of epilepsy by our standard practices had clinically relevant results.

pediatrics,clinical neurology
Novel Mutations and Phenotypes of Epilepsy-Associated Genes in Epileptic Encephalopathies.

P. Zhou,N. He,J. -W. Zhang,Z. -J. Lin,J. Wang,L. -M. Yan,H. Meng,B. Tang,B. -M. Li,X. -R. Liu,Y. -W. Shi,Q. -X. Zhai,Y. -H. Yi,W. -P. Liao

DOI: https://doi.org/10.1111/gbb.12456

2018-01-01

Abstract:Epileptic encephalopathies are severe epilepsy disorders with strong genetic bases. We performed targeted next-generation sequencing (NGS) in 70 patients with epileptic encephalopathies. The likely pathogenicity of variants in candidate genes was evaluated by American College of Medical Genetics and Genomics (ACMG) scoring taken together with the accepted clinical presentation. Thirty-three candidate variants were detected after population filtration and computational prediction. According to ACMG, 21 candidate variants, including 18 de novo variants, were assessed to be pathogenic/likely pathogenic with clinical concordance. Twelve variants were initially assessed as uncertain significance by ACMG, among which 3 were considered causative and 3 others were considered possibly causative after analysis of clinical concordance. In total, 24 variants were identified as putatively causative, among which 19 were novel findings. SCN1A mutations were identified in 50% of patients with Dravet syndrome. TSC1/TSC2 mutations were detected in 66.7% of patients with tuberous sclerosis. STXBP1 mutations were the main findings in patients with West syndrome. Mutations in SCN2A, KCNT1, KCNQ2 and CLCN4 were identified in patients with epileptic infantile with migrating focal seizures; among them, KCNQ2 and CLCN4 were first identified as potential causative genes. Only one CHD2 mutation was detected in patients with Lennox-Gastaut syndrome. This study highlighted the utility of targeted NGS in genetic diagnoses of epileptic encephalopathies and a comprehensive evaluation of the pathogenicity of variants based on ACMG scoring and assessment of clinical concordance. Epileptic encephalopathies differ in genetic causes, and the genotype-phenotype correlations would provide insights into the underlying pathogenic mechanisms.
Validation of targeted next-generation sequencing panels in a cohort of polish patients with epilepsy: assessing variable performance across clinical endophenotypes and uncovering novel genetic variants

Magdalena Badura-Stronka,Katarzyna Wołyńska,Anna Winczewska-Wiktor,Justyna Marcinkowska,Dagmara Karolewska,Danuta Tomkowiak-Kędzia,Michał Piechota,Marta Przyborska,Natalia Kochalska,Barbara Steinborn

DOI: https://doi.org/10.3389/fneur.2023.1316933

IF: 3.4

2024-01-13

Frontiers in Neurology

Abstract:Introduction: Targeted Next-Generation Sequencing Panels (TNGSP) have become a standard in global clinical practice. Instead of questioning the necessity of next-generation sequencing in epilepsy patients, contemporary large-scale research focuses on factors such as the size of TNGSP, the comparative advantages of exome or genome-wide sequencing over TNGSP, and the impact of clinical, electrophysiological, and demographic variables on genetic test performance. This study aims to elucidate the demographic and clinical factors influencing the performance of TNGSP in 138 Polish patients with epilepsy, recognizing the pivotal role of genetic testing in guiding patient management and therapy. Methods: A retrospective analysis was conducted on patients from a genetic clinic in Poznań, Poland, who underwent commercial gene panel studies at Invitae Corporation (USA) between 2020 and 2022. Patient groups were defined based on the age of onset of the first epileptic seizures, seizure type, gender, fever dependence of seizures, presence of intellectual disability or developmental delay, abnormalities in MRI, and the presence of dysmorphic features or congenital malformations. Seizure classification followed the 2017 ILAE criteria. Results: Among the 138 patients, 30 (21.7%) exhibited a pathogenic or likely pathogenic variant, with a distribution of 20.7% in males and 22.5% in females. Diagnostic performance correlated with the patient's age at the onset of the first seizure and the type of seizure. Predominant variants were identified in the SCN1A, PRRT2, CDKL5, DEPDC5, TSC2 , and SLC2A1 genes. Additionally, 12 genes ( CACNA1A, SCN2A, GRIN2A , KCNQ2, CHD2, DYNC1H1, NEXMIF, SCN1B, DDX3X, EEF1A2, NPRL3, UBE3A ) exhibited single instances of damage. Notably, novel variants were discovered in DEPDC5, SCN1A, TSC2, CDKL5, NPRL3, DYNC1H1, CHD2 , and DDX3X . Discussion: Identified variants were present in genes previously recognized in both European and non-European populations. A thorough examination of Variants of Uncertain Significance (VUSs), specifically focusing on gene copy number changes, may unveil more extensive chromosomal aberrations. The relatively frequent occurrence of pathological variants in X chromosome-linked genes in girls warrants further investigation, challenging the prevailing notion of male predominance in X-linked epilepsy.

neurosciences,clinical neurology
Computing Treewidth and Minimum Fill-In: All You Need are the Minimal Separators

T. Kloks,H. Bodlaender,H. Müller,D. Kratsch

DOI: https://doi.org/10.1007/3-540-57273-2_61

1993-09-30

Abstract:
Common genes and recurrent causative variants in 957 Asian patients with pediatric epilepsy

Se Hee Kim,Jieun Seo,Soon Sung Kwon,Lip-Yuen Teng,DongJu Won,Saeam Shin,Joon Soo Lee,Seung-Tae Lee,Jong Rak Choi,Hoon-Chul Kang

DOI: https://doi.org/10.1111/epi.17857

IF: 6.74

Epilepsia

Abstract:Objective: We aimed to identify common genes and recurrent causative variants in a large group of Asian patients with different epilepsy syndromes and subgroups. Methods: Patients with unexplained pediatric-onset epilepsy were identified from the in-house Severance Neurodevelopmental Disorders and Epilepsy Database. All patients underwent either exome sequencing or multigene panels from January 2017 to December 2019, at Severance Children's Hospital in Korea. Clinical data were extracted from the medical records. Results: Of the 957 patients studied, 947 (99.0%) were Korean and 570 were male (59.6%). The median age at testing was 4.91 years (interquartile range, 1.53-9.39). The overall diagnostic yield was 32.4% (310/957). Clinical exome sequencing yielded a diagnostic rate of 36.9% (134/363), whereas the epilepsy panel yielded a diagnostic rate of 29.9% (170/569). Diagnostic yield differed across epilepsy syndromes. It was high in Dravet syndrome (87.2%, 41/47) and early infantile developmental epileptic encephalopathy (60.7%, 17/28), but low in West syndrome (21.8%, 34/156) and myoclonic-atonic epilepsy (4.8%, 1/21). The most frequently implicated genes were SCN1A (n = 49), STXBP1 (n = 15), SCN2A (n = 14), KCNQ2 (n = 13), CDKL5 (n = 11), CHD2 (n = 9), SLC2A1 (n = 9), PCDH19 (n = 8), MECP2 (n = 6), SCN8A (n = 6), and PRRT2 (n = 5). The recurrent genetic abnormalities included 15q11.2 deletion/duplication (n = 9), Xq28 duplication (n = 5), PRRT2 deletion (n = 4), MECP2 duplication (n = 3), SCN1A, c.2556+3A>T (n = 3), and 2q24.3 deletion (n = 3). Significance: Here we present the results of a large-scale study conducted in East Asia, where we identified several common genes and recurrent variants that varied depending on specific epilepsy syndromes. The overall genetic landscape of the Asian population aligns with findings from other populations of varying ethnicities.
THz bandwidth optical switching with carbon nanotube metamaterial.

A. Nikolaenko,N. Papasimakis,A. Chipouline,F. De Angelis,E. Di Fabrizio,N. Zheludev

DOI: https://doi.org/10.1364/OE.20.006068

IF: 3.8

2012-03-12

Optics Express

Abstract:We provide the first demonstration of exceptional light-with-light optical switching performance of a carbon nanotube metamaterial - a hybrid nanostructure of a plasmonic metamaterial with semiconducting single-walled carbon nanotubes. A modulation depth of 10% in the near-IR with sub-500 fs response time is achieved with a pump fluence of just 10 μJ/cm², which is an order of magnitude lower than in previously reported artificial nanostructures. The improved switching characteristics of the carbon nanotube metamaterial are defined by an excitonic nonlinearity of carbon nanotubes resonantly enhanced by a concentration of local fields in the metamaterial. Since the spectral position of the excitonic response and metamaterial plasmonic resonance can be adjusted by using carbon nanotubes of different diameter and scaling of the metamaterial design, the giant nonlinear response of the hybrid metamaterial - in principle - can be engineered to cover the entire second and third telecom windows, from O- to U-band.

Preoperative autologous blood donations in pediatric cardiac surgery.

Next Generation Sequencing in Children with Unexplained Epilepsy: A Retrospective Cohort Study.

Clinical Utility of Exome Sequencing and Reinterpreting Genetic Test Results in Children and Adults With Epilepsy

Cowpea embryo rescue. 1. Influence of culture media composition on plant recovery from isolated immature embryos

Next-generation sequencing testing in children with epilepsy reveals novel clinical, diagnostic and therapeutic implications

High Diagnostic Yield and Clinical Utility of Next-Generation Sequencing in Children with Epilepsy and Neurodevelopmental Delays: A Retrospective Study

Utility of Genome Sequencing After Nondiagnostic Exome Sequencing in Unexplained Pediatric Epilepsy

Identification of genetic causes in children with unexplained epilepsy based on trio‐whole exome sequencing

C.1 Utility of genetic testing in the pre-surgical evaluation of children with drug-resistant epilepsy

Genetic testing in a cohort of patients with potential epilepsy with myoclonic-atonic seizures

Genetic Testing in the Presurgical Evaluation of Drug-Resistant Epilepsy: Bells and Whistles or Nuts and Bolts?

Scientific method in the evolution of new drugs; comparative biochemistry and the selection of possible pharmacologically active compounds.

Diagnostic yield of genetic testing in epileptic encephalopathy in childhood

Exome sequencing identifies molecular diagnosis in children with drug-resistant epilepsy

Utility of genetic testing in the pre-surgical evaluation of children with drug-resistant epilepsy

Yield and Utility of Routine Epilepsy Panel Genetic Testing Among Young Patients With Seizures

Novel Mutations and Phenotypes of Epilepsy-Associated Genes in Epileptic Encephalopathies.

Validation of targeted next-generation sequencing panels in a cohort of polish patients with epilepsy: assessing variable performance across clinical endophenotypes and uncovering novel genetic variants

Computing Treewidth and Minimum Fill-In: All You Need are the Minimal Separators

Common genes and recurrent causative variants in 957 Asian patients with pediatric epilepsy

THz bandwidth optical switching with carbon nanotube metamaterial.